Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Net Income of $3.95 billion for fiscal year 2025.
VERTEX PHARMACEUTICALS INC / MA Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $3.95B | +838.1% |
| 2024 | -$535.60M | -114.8% |
| 2023 | $3.62B | +9.0% |
| 2022 | $3.32B | +41.8% |
| 2021 | $2.34B | -13.6% |
| 2020 | $2.71B | +130.4% |
| 2019 | $1.18B | -43.9% |
| 2018 | $2.10B | +695.8% |
| 2017 | $263.48M | +335.1% |
| 2016 | -$112.05M | +79.9% |
| 2015 | -$556.33M | +24.7% |
| 2014 | -$738.55M | -66.0% |
| 2013 | -$445.03M | -315.8% |
| 2012 | -$107.03M | -461.9% |
| 2011 | $29.57M | +103.9% |
| 2010 | -$754.63M | -17.5% |
| 2009 | -$642.18M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.08B | +3.6% | +4.8% |
| June 30, 2025 | $1.03B | +128.7% | +59.8% |
| March 31, 2025 | $646.30M | -41.2% | -38.2% |
| September 30, 2024 | $1.05B | +1.0% | +129.1% |
| June 30, 2024 | -$3.59B | -492.4% | -426.8% |
| March 31, 2024 | $1.10B | +57.1% | +6.2% |
| September 30, 2023 | $1.04B | +11.3% | +13.1% |
| June 30, 2023 | $915.70M | +13.0% | +30.9% |
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +838.1% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, VERTEX PHARMACEUTICALS INC / MA’s net income has grown by 715.6% (from -$642.18 million to $3.95 billion).
- The most recent figure is from VERTEX PHARMACEUTICALS INC / MA’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: